{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=31",
    "query": {
      "intervention": "Genotyping",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 732,
    "total_pages": 74,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Genotyping&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T00:01:43.734Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05277363",
      "title": "A Study of the Natural Course of SURF1 Deficiency",
      "overall_status": "WITHDRAWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Leigh Syndrome"
      ],
      "interventions": [
        {
          "name": "None (Observational study)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Taysha Gene Therapies, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "Up to 18 Years"
      },
      "enrollment_count": 0,
      "start_date": "2022-05-04",
      "completion_date": "2022-05-04",
      "has_results": false,
      "last_update_posted_date": "2022-05-20",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05277363"
    },
    {
      "nct_id": "NCT02293096",
      "title": "Pharmacogenetic Prediction of Metoprolol Effectiveness",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "metoprolol succinate",
          "type": "DRUG"
        },
        {
          "name": "Genotyping",
          "type": "GENETIC"
        },
        {
          "name": "CYP2D6 Phenotyping",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "GENETIC",
        "PROCEDURE"
      ],
      "sponsor": "University of Colorado, Denver",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "30 Years to 80 Years"
      },
      "enrollment_count": 462,
      "start_date": "2014-09",
      "completion_date": "2017-08-23",
      "has_results": true,
      "last_update_posted_date": "2021-09-16",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Aurora, Colorado",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02293096"
    },
    {
      "nct_id": "NCT01890772",
      "title": "Vitamin D + Telaprevir + Peginterferon + Ribavirin for of Hepatitis C Genotype 1",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Telaprevir",
          "type": "DRUG"
        },
        {
          "name": "Peginterferon alfa-2a",
          "type": "DRUG"
        },
        {
          "name": "Ribavirin",
          "type": "DRUG"
        },
        {
          "name": "Vitamin D",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "Timothy Morgan, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2013-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-05-14",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 4,
      "location_summary": "Long Beach, California • Minneapolis, Minnesota • Kansas City, Missouri + 1 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01890772"
    },
    {
      "nct_id": "NCT01188772",
      "title": "Sofosbuvir in Combination With Pegylated Interferon and Ribavirin and in Treatment-Naive Hepatitis C-infected Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hepatitis C Virus"
      ],
      "interventions": [
        {
          "name": "Sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "Placebo to match sofosbuvir",
          "type": "DRUG"
        },
        {
          "name": "PEG",
          "type": "DRUG"
        },
        {
          "name": "RBV",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 147,
      "start_date": "2010-08",
      "completion_date": "2012-05",
      "has_results": true,
      "last_update_posted_date": "2014-04-21",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 22,
      "location_summary": "Montgomery, Alabama • Anaheim, California • Coronado, California + 17 more",
      "locations": [
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Coronado",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01188772"
    },
    {
      "nct_id": "NCT05668741",
      "title": "A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cystic Fibrosis"
      ],
      "interventions": [
        {
          "name": "VX-522 mRNA therapy",
          "type": "DRUG"
        },
        {
          "name": "IVA",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vertex Pharmaceuticals Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 26,
      "start_date": "2023-02-27",
      "completion_date": "2026-09-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-09",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Long Beach, California • Palo Alto, California + 9 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05668741"
    },
    {
      "nct_id": "NCT02191267",
      "title": "Tau Imaging of Chronic Traumatic Encephalopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Chronic Traumatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "[F18]-T807",
          "type": "RADIATION"
        },
        {
          "name": "[F18]-Florbetapir",
          "type": "RADIATION"
        },
        {
          "name": "MRI/MRS",
          "type": "DEVICE"
        },
        {
          "name": "Genetic Analysis for Genetic Risk Score for Tau.",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE",
        "GENETIC"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "69 Years",
        "sex": "MALE",
        "summary": "40 Years to 69 Years · Male only"
      },
      "enrollment_count": 30,
      "start_date": "2015-01",
      "completion_date": "2016-09-30",
      "has_results": true,
      "last_update_posted_date": "2018-05-17",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02191267"
    },
    {
      "nct_id": "NCT00752687",
      "title": "A Study of ABT-072 in Healthy and Hepatitis C Virus Genotype 1-Infected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "ABT-072",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Abbott",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 100,
      "start_date": "2008-09",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-10-21",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Abbott Park, Illinois",
      "locations": [
        {
          "city": "Abbott Park",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00752687"
    },
    {
      "nct_id": "NCT01857245",
      "title": "Intensive Models of HCV Care for Injection Drug Users",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Hepatitis C",
        "Medication Adherence"
      ],
      "interventions": [
        {
          "name": "Intensive Models (mDOT and CGT) of HCV Care",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Prisma Health-Upstate",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2013-10-01",
      "completion_date": "2017-04-30",
      "has_results": true,
      "last_update_posted_date": "2025-02-03",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Greenville, South Carolina",
      "locations": [
        {
          "city": "Greenville",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01857245"
    },
    {
      "nct_id": "NCT05183828",
      "title": "Effect of HSD3B1 (1245C) Gene Mutation on Treatment of Stage I-III Breast Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Anatomic Stage I Breast Cancer AJCC v8",
        "Anatomic Stage II Breast Cancer AJCC v8",
        "Anatomic Stage III Breast Cancer AJCC v8",
        "Breast Adenocarcinoma",
        "Invasive Breast Carcinoma of No Special Type"
      ],
      "interventions": [
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Questionnaire Administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 62,
      "start_date": "2022-01-23",
      "completion_date": "2026-05-13",
      "has_results": false,
      "last_update_posted_date": "2026-06-04",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05183828"
    },
    {
      "nct_id": "NCT00589225",
      "title": "Primary Hyperoxaluria Mutation Genotyping",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Primary Hyperoxaluria"
      ],
      "interventions": [
        {
          "name": "Genetic Analysis",
          "type": "GENETIC"
        }
      ],
      "intervention_types": [
        "GENETIC"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 902,
      "start_date": "2003-12",
      "completion_date": "2014-09",
      "has_results": false,
      "last_update_posted_date": "2016-07-07",
      "last_synced_at": "2026-10-23T00:01:43.734Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00589225"
    }
  ]
}